Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

723
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
723
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

48
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
48
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

59
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
59
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

47
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
47
Angina IV: Management01:26

Angina IV: Management

44
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
44
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

29
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
29

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Application of the Three Delays Framework to Assess Barriers to Surgical Care in an East African Refugee Camp: A Cross-sectional Survey Among 1,135 Adults.

The Journal of surgical research·2026
Same author

Trainee and Faculty Perspectives on Global Oncology: Assessing Interest, Barriers, and Opportunities.

Journal of cancer education : the official journal of the American Association for Cancer Education·2026
Same author

Implementation of wellness activities in an experiential rotation to promote pharmacy student well-being.

Currents in pharmacy teaching & learning·2026
Same author

Protecting Children This World Health Day: The Case for Early Childhood Cancer Detection Through Primary Health Care Strengthening in Vietnam.

Pediatric blood & cancer·2026
Same author

Magnetic resonance imaging-based proton dose calculation for pelvic tumors using deep learning.

Physics in medicine and biology·2026
Same author

Phase 1 study of mebendazole therapy for refractory/progressive or recurrent pediatric brain tumors.

Neuro-oncology practice·2025

Related Experiment Video

Updated: Oct 8, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.3K

Antiplatelet Therapy in Older Patients Post-Myocardial Infarction.

Hindu Rao1, Paul Phan1, Megan Eclevia1

  • 1Chapman University Irvine, California.

The Senior Care Pharmacist
|December 26, 2021
PubMed
Summary

This case study examines antiplatelet therapy for elderly patients after myocardial infarction and stent placement. It highlights crucial factors for selecting optimal treatment, balancing benefits against risks like adverse effects and drug interactions.

More Related Videos

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.4K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.1K

Related Experiment Videos

Last Updated: Oct 8, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.3K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.4K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.1K

Area of Science:

  • Cardiology
  • Geriatric Medicine
  • Pharmacology

Background:

  • Older adults present unique challenges in managing cardiovascular conditions.
  • Myocardial infarction and stent placement necessitate antiplatelet therapy.

Purpose of the Study:

  • To review antiplatelet treatment strategies for elderly patients post-myocardial infarction and stent.
  • To investigate the benefits and risks of antiplatelet agents in this demographic.

Main Methods:

  • Case study review.
  • Analysis of patient- and drug-specific factors influencing treatment selection.

Main Results:

  • Identification of key considerations for antiplatelet therapy in older patients.
  • Evaluation of adverse effects and drug interactions relevant to geriatric populations.

Conclusions:

  • Tailoring antiplatelet therapy is essential for older patients.
  • Careful consideration of individual patient factors and drug profiles optimizes outcomes.